Beyond here be dragons: SIBO in Parkinson's disease

Movement Disorders

Volumn 28, Issue 13, 2013, Pages 1764-1765

  Pfeiffer, Ronald ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT; PROKINETIC AGENT;

ANTIBIOTIC THERAPY; BACTERIAL OVERGROWTH; BREATH ANALYSIS; EDITORIAL; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; SMALL INTESTINAL BACTERIAL OVERGROWTH; STOMACH EMPTYING; STOMACH PARESIS;

ENTERITIS; FEMALE; HELICOBACTER INFECTIONS; HUMANS; INTESTINE, SMALL; MALE; PARKINSON DISEASE;

EID: 84887619366     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25705     Document Type: Editorial

References (19)

1. Lewitan A, Nathanson L, Slade WR Jr. Megacolon and dilatation of the small bowel in parkinsonism. Gastroenterology 1951;17:367-374.
2. Eaker EY, Bixler GB, Dunn AJ, Moreshead WV, Mathias JR. Chronic alterations in jejunal myoelectric activity in rats due to MPTP. Am J Physiol 1987;253:G809-G815.
3. Banach T, Zurowski D, Kania D, Thor PJ. Myoelectrical activity of small intestine in rats with experimental Parkinson's disease. Folia Med Cracov 2005;46:119-124.
4. Davies KN, King D, Billington D, Barrett JA. Intestinal permeability and orocaecal transit time in elderly patients with Parkinson's disease. Postgrad Med J 1996;72:164-167.
5. Fasano A, Bove F, Gabrielli M, et al. The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2013;28:1241-1249.
6. Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011;26:889-892.
7. Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutr Clin Pract 2013;28:289-299.
8. Grace E, Shaw C, Whelan K, Andreyev HJN. Review article: small intestinal bacterial overgrowth - prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013;38:674-688.
9. Khoshini R, Dai S-C, Lezcano S, Pimentel M. A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci 2008;53:1443-1454.
10. Scarpellini E, Gabrielli M, Lauritano CE, et al. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007;25:781-786.
11. Rivkin A, Gim S. Rifaximin: new therapeutic indication and future directions. Clin Ther 2011;33:812-827.
12. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011;17:10-15.
13. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010;8:504-508.
14. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011;41:380-386.
15. Dobbs RJ, Charlett A, Dobbs SM, et al. Towards defining a rigidity-#associated pathogenic pathway in idiopathic parkinsonism. Neurodegener Dis 2012;10:183-186.
16. Rees K, Stowe R, Patel S, et al. Helicobacter pylori eradication for Parkinson's disease. Cochrane Database Syst Rev 201;CD008453.
17. Nielsen HH, Qiu J, Friis S, Wermuth L, Ritz B. Treatment for Helicobacter pylori infection and risk of Parkinson's disease in Denmark. Eur J Neurol 2012;19:864-869.
18. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis 2012;13:342-349.
19. Rahne KE, Tagesson C, Nyholm D. Motor fluctuations and Helicobacter pylori in Parkinson's disease. J Neurol 2013; doi: 10.1007/s00415-013-7089-6.